Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Read more
Subcategories of "Tyrosine Kinase/Adaptors"
ALK
CSF-1R
EGFR
Ephrin Receptor
FLT
Fibroblast Growth Factor Receptor (FGFR)
HER
Hck
IGF-1R
PDGFR
PYK2
Src
TAM Receptor
Tie-2
Trk receptor
Tyrosine Kinases
VEGFR
c-Fms
c-Kit
c-Met/HGFR
c-RET
Show 13 more subcategories
Products of "Tyrosine Kinase/Adaptors"
PROTAC BTK Degrader-5
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a …
Formula:
C52H57ClFN9O6
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
958.52
Ref: TM-T79292
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
Oligopeptide-41
Oligopeptide-41 is a bioactive peptide known for its hair growth-promoting effects and is reported to …
Formula:
C63H90N18O19S
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
1435.56
Ref: TM-T80206
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
T-1-MCPAB
T-1-MCPAB, a VEGFR-2 inhibitor with an IC50 of 0.135 µM, effectively suppresses MCF7 cell migration …
Purity:
98%
Ref: TM-T81054
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
Ranibizumab
CAS:347396-82-1
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth …
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
149.19KD
Ref: TM-T9928
| 1mg | 305.00 € | ||
| 5mg | 815.00 € | ||
| 10mg | 1,303.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
Disitamab vedotin
CAS:2136633-23-1
Disitamab vedotin (RC-48) is a HER2-targeting ADC with MMAE, effective in HER2-expressing gastric cancer.
Purity:
95.00% - 98%
Color and Shape:
Liquid
Molecular weight:
Approximately 144.15 kDa
Ref: TM-T39595
| 1mg | 324.00 € | ||
| 5mg | 783.00 € | ||
| 10mg | 1,083.00 € | ||
| 25mg | 1,606.00 € | ||
| 50mg | 2,166.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
PF-04217903 phenolsulfonate
CAS:1159490-85-3
PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for …
Formula:
C25H22N8O5S
Purity:
98%
Color and Shape:
Solid
Molecular weight:
546.56
Ref: TM-T12418
| 25mg | 1,432.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
Pimurutamab
CAS:2251771-76-1
Pimurutamab, a humanized IgG1-κ antibody, selectively targets the epidermal growth factor receptor (EGFR) and is …
Purity:
98%
Color and Shape:
Liquid
Ref: TM-T80612
| 1mg | To inquire | ||
| 5mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
Acrizanib
CAS:1229453-99-9
Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2.
Formula:
C20H18F3N7O2
Purity:
98.71% - 98.72%
Color and Shape:
Solid
Molecular weight:
445.4
Ref: TM-T5373
| 1mg | 109.00 € | ||
| 5mg | 269.00 € | ||
| 10mg | 414.00 € | ||
| 25mg | 707.00 € | ||
| 50mg | 984.00 € | ||
| 100mg | 1,281.00 € | ||
| 1mL*10mM (DMSO) | 295.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
Pertuzumab
CAS:380610-27-5
Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called …
Purity:
98.00%
Color and Shape:
Liquid
Molecular weight:
148 kDa
Ref: TM-T9909
| 1mg | 177.00 € | ||
| 5mg | 537.00 € | ||
| 10mg | 773.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
EGFR/HER2/DHFR-IN-3
EGFR/HER2/DHFR-IN-3 (compound 4c) serves as an efficacious dual inhibitor specifically targeting EGFR/HER2, exhibiting IC50 values …
Purity:
98%
Ref: TM-T82492
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
Taletrectinib free base
CAS:1505514-27-1
Taletrectinib (AB-106) is a potent, selective oral ROS1/NTRK inhibitor with low IC50s against ROS1 and …
Formula:
C23H24FN5O
Purity:
99.87%
Color and Shape:
Liquid
Molecular weight:
405.47
Ref: TM-T38995
| 1mg | 70.00 € | ||
| 5mg | 153.00 € | ||
| 10mg | 238.00 € | ||
| 25mg | 480.00 € | ||
| 50mg | 690.00 € | ||
| 100mg | 975.00 € | ||
| 1mL*10mM (DMSO) | 182.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
hCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes …
Formula:
C23H26N6O5S
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
498.55
Ref: TM-T79587
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
GIP (3-42), human
CAS:1802086-25-4
Human GIP (3-42) is a peptide antagonist of GIP receptors, affecting insulin regulation and diabetes …
Formula:
C214H324N58O63S
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
4749.35
Ref: TM-T37589
| 1mg | 185.00 € | ||
| 5mg | 459.00 € | ||
| 10mg | 656.00 € | ||
| 25mg | 1,027.00 € | ||
| 50mg | 1,403.00 € | ||
| 100mg | 1,865.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
WAY-270360
CAS:476633-98-4
WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.
Formula:
C22H19N3O3
Purity:
98.66%
Color and Shape:
Liquid
Molecular weight:
373.4
Ref: TM-T60064
| 1mg | 63.00 € | ||
| 5mg | 137.00 € | ||
| 10mg | 184.00 € | ||
| 25mg | 324.00 € | ||
| 50mg | 455.00 € | ||
| 100mg | 641.00 € | ||
| 500mg | 1,272.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
EGFR-IN-90
EGFR-IN-90 (compound 34), an orally active EGFR inhibitor, demonstrates potent activity against EGFRL858R/T790M/C797S with an …
Purity:
98%
Ref: TM-T82491
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
Inetetamab
Inetetamab, a monoclonal antibody, targets domain IV of the HER2 receptor and demonstrates antitumor activities …
Purity:
98%
Ref: TM-T78335
| 1mg | To inquire | ||
| 5mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
FGFR1 inhibitor-9
FGFR1 inhibitor-9 (Compound 7) is an FGFR1 inhibitor with potent binding affinity, exhibiting an IC50 …
Formula:
C27H20ClNO5
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
473.9
Ref: TM-T78832
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
Mutated EGFR-IN-3
CAS:2375107-27-8
Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.
Formula:
C31H29FN4O2
Purity:
98%
Color and Shape:
Solid
Molecular weight:
508.59
Ref: TM-T12131
| 25mg | 1,435.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
AZ12672857
CAS:945396-55-4
AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.
Formula:
C26H30N8O2
Purity:
98.05%
Color and Shape:
Solid
Molecular weight:
486.57
Ref: TM-T9650
| 1mg | 69.00 € | ||
| 2mg | 91.00 € | ||
| 5mg | 152.00 € | ||
| 10mg | 254.00 € | ||
| 25mg | 416.00 € | ||
| 50mg | 648.00 € | ||
| 100mg | 877.00 € | ||
| 1mL*10mM (DMSO) | 165.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
Varlitinib
CAS:845272-21-1
Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, …
Formula:
C22H19ClN6O2S
Purity:
99.7%
Color and Shape:
Solid
Molecular weight:
466.94
Ref: TM-T6719
| 1mg | 35.00 € | ||
| 5mg | 62.00 € | ||
| 10mg | 99.00 € | ||
| 25mg | 165.00 € | ||
| 50mg | To inquire | ||
| 1mL*10mM (DMSO) | 72.00 € |
Estimated delivery in United States, on Monday 2 Dec 2024
